ArticleAnnals of surgical oncology2013
Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?
Article in Annals of surgical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sentinel Lymph Node Biopsy for Desmoplastic Melanoma: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Pooled it
- Desmoplastic melanoma in Sweden in 2009-2022: A population-based registry study demonstrating distinctive tumour characteristics, incidence and survival trends.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- An Evaluation of Sentinel Lymph Node Biopsy Guideline Adherence in Melanoma.Annals of surgical oncology · 2025Article
- Clinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes.Cancers · 2024Review
- Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management.Pathology · 2023Article
- Surgical Management of Melanoma: Advances and Updates.Current oncology reports · 2022Review
- Pure and Mixed Desmoplastic Melanomas: A Retrospective Clinicopathologic Comparison of 33 Cases.The American Journal of dermatopathology · 2021Article
- Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma.Current treatment options in oncology · 2021Review
- Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas.Annals of surgical oncology · 2021Article
- Desmoplastic Melanoma: A Clinicopathological Analysis of Three Cases in the Chinese Population.OncoTargets and therapy · 2021Article
- Desmoplastic melanoma: The role of pure and mixed subtype in sentinel lymph node biopsy and survival.Cancer medicine · 2020Article
- Desmoplastic melanoma involving head and fingers: diagnostic challenges and clinical characteristics.International journal of clinical and experimental pathology · 2019Article
- [Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
- [Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].Der Pathologe · 2017Article
- Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.World journal of clinical oncology · 2016Review
- EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma.European journal of nuclear medicine and molecular imaging · 2015Article
- Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.Cancer · 2015Article
- Article
- Article
- Sentinel Node Biopsy in Melanoma: A Short Update.Dermatopathology (Basel, Switzerland)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe utility of sentinel lymph node biopsy (SLNB) for desmoplastic melanoma (DM) is debated. We describe a large single-institution experience with SLNB for DM to determine clinicopathologic factors predictive of SLN metastasis.
methodsRetrospective review identified 205 patients with DM who underwent SLNB from 1992 to 2010. Clinicopathologic characteristics were correlated with SLN status and outcome.
resultsMedian age was 66 years, and 69 % of patients were male. Median Breslow thickness was 3.7 mm. In 128 cases (62 %), histologic subtype data was available; 61 cases (47.7 %) were mixed and 67 cases (52.3 %) were pure DM. A positive SLN was found in 28 cases (13.7 %); 24.6 % of mixed and 9 % of pure DM had SLN metastases. Multivariable analysis demonstrated that after controlling for age, histologic subtype correlated with SLN status [odds ratio: 3.0 for mixed vs pure, 95 % confidence interval: 1.1-8.7; p < .05]. Completion lymph node dissection was performed in 24 of 28 positive SLN patients with 16.7 % of cases having additional nodal disease. After a median follow-up of 6.3 years, 38 patients developed recurrence and 61 patients died. Positive SLN patients had a significantly higher risk of melanoma-related death compared with negative SLN patients (p = .01).
conclusionsThe overall risk for SLN metastasis for DM is 13.7 % and is significantly higher for mixed (24.6 %) compared with pure (9.0 %) DM. We believe that these rates are sufficient to justify consideration of SLNB for both histologic variants, especially since detection of SLN disease appears to predict a higher risk for melanoma-related death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.